• One Health
  • Pain Management
  • Oncology
  • Geriatric & Palliative Medicine
  • Ophthalmology
  • Anatomic Pathology
  • Poultry Medicine
  • Infectious Diseases
  • Dermatology
  • Theriogenology
  • Nutrition
  • Animal Welfare
  • Radiology
  • Internal Medicine
  • Small Ruminant
  • Cardiology
  • Dentistry
  • Feline Medicine
  • Soft Tissue Surgery
  • Urology/Nephrology
  • Avian & Exotic
  • Preventive Medicine
  • Anesthesiology & Pain Management
  • Integrative & Holistic Medicine
  • Food Animals
  • Behavior
  • Zoo Medicine
  • Toxicology
  • Orthopedics
  • Emergency & Critical Care
  • Equine Medicine
  • Pharmacology
  • Pediatrics
  • Respiratory Medicine
  • Shelter Medicine
  • Parasitology
  • Clinical Pathology
  • Virtual Care
  • Rehabilitation
  • Epidemiology
  • Fish Medicine
  • Diabetes
  • Livestock
  • Endocrinology

FDA to address veterinary antiparasitic use and resistance in equines, ruminants


Rockville, Md. -- The Food and Drug Administration (FDA) plans to tackle anthelmintic resistance in horses and ruminants during a two-day public meeting in March.

Rockville, Md. --

The Food and Drug Administration (FDA) plans to tackle anthelmintic resistance during a two-day symposium in March.

While the meeting is focused on horses and ruminants, topics will cover the development of tools for the evaluation of antiparasitic resistance, evaluation of the effectiveness of drugs against resistant parasites, and the scientific rationale for the use of combinations of antiparasitic drugs in ruminants and equines.

The meeting is slated for March 5-6 at the Hilton Rockville Hotel here.

The main purpose of the meeting is to explore and discuss ways in which antiparasitic drugs can be used, alone or in combination to maximize antiparasitic drug efficacy and minimize development of parasitic resistance in ruminant and equine species.

The meeting is open to the public and interested persons may make written or oral presentations on this subject. Written submissions may be made to Aleta Sindelar, Aleta.Sindelar@fda.hhs.gov, CVM (HFV-3), FDA, 7519 Standish Place, Rockville, MD 20855 by Feb. 27, 2012.

Those people interested in making an oral statement should notify Sindelar on or before Feb. 20. Time allotted for each presentation may be limited, FDA says.

Related Videos
© 2023 MJH Life Sciences

All rights reserved.